|1.||Nagahara, T: 1 article (09/2008)|
|2.||Isobe, K: 1 article (09/2008)|
|3.||Morishima, Y: 1 article (09/2008)|
|4.||Sugiyama, N: 1 article (09/2008)|
|5.||Honda, Y: 1 article (09/2008)|
|6.||Furugohri, T: 1 article (09/2008)|
|7.||Shibano, T: 1 article (09/2008)|
|8.||Kamisato-Matsumoto, C: 1 article (09/2008)|
|9.||Gaztanaga, Juan: 1 article (10/2007)|
|10.||Kunitada, Satoshi: 1 article (10/2007)|
09/01/2008 - "In vivo, DU-176b dose-dependently inhibited thrombus formation in rat and rabbit thrombosis models, although bleeding time in rats was not significantly prolonged at an antithrombotic dose. "
09/01/2008 - "To evaluate the in vitro pharmacological profiles and in vivo effects of DU-176b in animal models of thrombosis and bleeding. "
10/01/2007 - "Direct and specific inhibition of factor Xa by DU-176b significantly reduced ex-vivo thrombus formation at both venous and arterial rheologies, up to 5 hours post-dose. "
09/01/2007 - "Daiichi Sankyo Inc (formerly Daiichi Seiyaku Co Ltd) is developing DU-176b, a direct, orally active Factor Xa inhibitor, as an anticoagulant for the potential treatment of cardiovascular indications, including venous and arterial thrombosis. "
|1.||Factor Xa (Coagulation Factor Xa)